Valuation: Healios K.K.

Market Cap 34.97B 221M 197M 182M 165M 311M 20.95B 316M 2.19B 860M 10.96B 829M 812M P/E 2026 *
-6.42x
P/E 2027 * -11.3x
Enterprise Value 34.71B 219M 195M 181M 164M 308M 20.79B 314M 2.17B 853M 10.88B 823M 806M EV / Sales 2026 *
68.7x
EV / Sales 2027 * 9.74x
Free-Float
79.1%
Yield 2026 *
-
Yield 2027 * -
10-05 Healios Completes First 144 Million Yen Culture Supernatant Shipment to JENECEL MT
09-30 Healios K.K. Announces Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL CI
07-27 Healios Announces Selection of Akt-01/Hlcn061 Commercial Manufacturing Process for Amed Project CI
04-08 Japan Stocks Rise as US-Iran Ceasefire Eases Geopolitical Concerns MT
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
04-07 Healios to Supply Stem Cell Culture Material to JENECELL in Cosmetics Deal MT
04-07 Healios K.K. Enters Agreement with Jenecell to Supply Culture Supernatant CI
03-27 Healios K.K. Receives Grant Approval from Ministry of Economy, Trade and Industry for Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities CI
02-20 Healios Plans Capital Reduction to Eliminate Retained Losses MT
02-12 Healios K.K. announced that it has received ¥6.2985881 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
02-03 Healios K.K. Announces Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-28 Healios K.K. announced that it expects to receive ¥6.2985881 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
1 day+8.53%
1 week-4.11%
Current month-6.04%
1 month-4.76%
3 months+7.28%
6 months-24.53%
Current year+2.19%
1 week 256
Extreme 256
289
1 month 256
Extreme 256
318
Current year 208
Extreme 208
483
1 year 208
Extreme 208
514
3 years 114
Extreme 114
747
5 years 114
Extreme 114
1,807
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 73 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+8.53%-4.11%-41.18%+84.21% 221M
+0.79%-6.16%+49.32%+74.50% 66.34B
+1.92%+10.35%+13.02%+87.74% 52.92B
+6.91%+8.57%+6.88%+72.12% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.22%-0.60%+37.26%+7.13% 26.17B
+2.36%+5.34%+30.98%+26.07% 23.37B
Average +3.14%+0.41%+42.42%+119.17% 38.77B
Weighted average by Cap. +2.78%+1.98%+51.04%+127.80%

Financials

2026 *2027 *
Net sales 505M 3.2M 2.84M 2.64M 2.39M 4.49M 303M 4.56M 31.63M 12.43M 158M 11.99M 11.74M 3.74B 23.66M 21.06M 19.52M 17.69M 33.24M 2.24B 33.8M 234M 92.02M 1.17B 88.76M 86.92M
Net income -3.63B -22.94M -20.42M -18.92M -17.15M -32.22M -2.17B -32.76M -227M -89.2M -1.14B -86.04M -84.25M -1.81B -11.43M -10.17M -9.43M -8.54M -16.05M -1.08B -16.32M -113M -44.44M -567M -42.87M -41.98M
Net Debt -260M -1.64M -1.46M -1.36M -1.23M -2.31M -156M -2.35M -16.26M -6.39M -81.44M -6.16M -6.03M 1.46B 9.25M 8.23M 7.63M 6.92M 13M 876M 13.21M 91.57M 35.97M 459M 34.7M 33.98M
Projected Income Statement - Annual - Healios K.K.
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-10-21 JP¥280.00 +8.53% 1,626,800
26-10-20 JP¥258.00 -4.09% 1,645,400
26-10-19 JP¥269.00 -4.27% 1,289,200
26-10-16 JP¥281.00 +2.18% 1,162,600
26-10-15 JP¥275.00 -5.82% 1,881,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Healios K.K.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
258.00JPY
Average target price
794.83JPY
Spread / Average Target
+208.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Healios K.K.
  1. Stock Market
  2. Stocks
  3. 4593 Stock